Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Yshay Shlesinger MD

Neither a doctor nor a teaching hospital

Research payments

$2,095,420

54 payments

Through program year 2025, Yshay Shlesinger MD is reported as receiving $2,095,420 in research payments, across 54 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $618,301 17
2024 Research $625,319 15
2023 Research $351,455 12
2022 Research $469,537 5
2021 Research $17,246 3
2020 Research $13,563 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $2,089,090 53 payments
  2. Eli Lilly Export S.A. Puerto Rico Branch $6,330 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $772,535 6 payments
  2. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $468,201 3 payments
  3. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $311,859 3 payments
  4. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity Or Overweight With and Without Type 2 Diabetes: J2a-Mc-Gzp1, J2a-Mc-Gzp2 $203,480 2 payments
  5. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $117,470 3 payments
  6. A Study of Orforglipron (Ly3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (Achieve-1) $101,422 4 payments
  7. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $39,333 10 payments
  8. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $26,587 3 payments
  9. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $15,388 4 payments
  10. A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Ly3841136 and Tirzepatide, Alone Or in Combination, in Adult Participants With Obesity Or Overweight With Type 2 Diabetes $9,760 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record